A 2-pronged attack could improve colon cancer therapy by Amirah Al Idrus Wednesday, May 16, 2018 Researchers in Germany pinpointed why targeting Notch and MAPK signaling individually may actually exacerbate colon cancer.
Sanofi, Evotec in infectious disease R&D transfer and license deal by Ben Adams Thursday, March 8, 2018 Sanofi will license out a host of infectious disease assets to Evotec, with 100 staffers also moving into its R&D engine.
Magenta inks deal with Heidelberg on stem cell transplants by Phil Taylor Tuesday, March 6, 2018 Magenta could pay the German biotech up to $334 million in milestones if the antibody drug conjugate pacts hit their targets.
Medigene gets OK for first trial of T-cell receptor therapy by Phil Taylor Wednesday, February 21, 2018 Medigene has been given a green light in Germany to start human trials of MDG1011, the lead candidate to come out of its modified T-cell program.
Biofrontera files for IPO to run skin cancer clinical trials by Nick Paul Taylor Monday, January 15, 2018 The German company is seeking $22 million to support a clutch of clinical trials designed to expand use of Ameluz in types of skin cancer.
Boehringer more than doubles VC fund with boosted focus, reach by Ben Adams Wednesday, January 3, 2018 Boehringer Ingelheim is deepening its venture fund pockets from €100 million to €250 million as it looks to change up its investment strategy.
Bayer signs another $1B R&D pact by Ben Adams Monday, November 20, 2017 Bayer has signed a potentially major research pact with Japan’s PeptiDream, marking the second big biobucks deal for the German pharma in the past week.
Evotec pairs with Tesaro to seek out new immuno-oncology targets by Ben Adams Thursday, October 26, 2017 Germany’s Evotec has penned another deal amid a stream of R&D pacts over the past year, this time with PARP player Tesaro.
Improving stem cell transplants for blood cancers by Amirah Al Idrus Friday, September 8, 2017 Temporarily blocking two proteins promoted the efficacy of stem cell transplants without causing harmful side effects to the patient.
AstraZeneca inks respiratory disease mRNA pact with Ethris by Nick Paul Taylor Monday, August 21, 2017 The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.
